They suggest that anti-PDL1 therapy could be a reference therapy for evaluating the effectiveness of targeted therapies being developed for KRAS-mutant NSCLC patients, especially the subgroup with the KRAS G12C mutation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.